New Initiative Targets 11 Neglected Infectious Diseases
A new research program aims to reduce development costs for treatments targeting 11 global infectious diseases.
Updated on Sept. 22, 2026 in Diseases — General
Live Poll
Should private companies prioritize research for neglected diseases over profitable drug development projects?
Seek Labs has launched the Open Impact Sequence Ablation Therapeutics Program to accelerate research for 11 neglected infectious diseases. The three-year initiative aims to address conditions often overlooked by traditional commercial drug development markets.
Why it matters
By providing technical designs and intelligence without upfront licensing costs, the program seeks to lower barriers to developing much-needed therapies. This model is designed to attract sustained investment for diseases that currently lack adequate medical resources.
Seek Labs has established an initiative targeting 11 infectious diseases using BioSeeker intelligence, which currently covers 95 percent of the global infectious-disease burden. These Sequence Ablation Therapeutics are currently investigational and lack FDA or USDA approval.
The players
Seek Labs
A Salt Lake City-based research organization focused on developing therapeutic technologies and intelligence for global health challenges.
Clinton Global Initiative
An organization that convenes global leaders and partners to develop and implement solutions to pressing world challenges.
The details
The program functions through an open-access exchange of technical instructions and BioSeeker intelligence. Research partners use these designs to conduct laboratory validation and return experimental data to refine the therapeutics, creating a continuous improvement loop. This collaborative approach focuses on creating Sequence Ablation Therapeutics that are intended to be more accessible than traditional market-driven options.
Timeline
September 22, 2026: Seek Labs announced the Open Impact program.
The initiative is scheduled to span a three-year duration.
Health Landscape
The Open Impact program attempts to bridge the gap in therapeutic development for diseases historically underserved by commercial markets. It builds upon the broader effort to map global disease burdens to identify where new technical interventions are most urgently required.
This program is in the early research phase and does not currently affect clinical care or treatment availability. Patients or families interested in specific therapies for these conditions should discuss current standards of care with their physician rather than anticipating immediate new options.
The takeaway
The program highlights an emerging model for accelerating research on diseases with limited commercial interest. It is useful to track these developments as potential future treatment options that may eventually reach human clinical trials.
Further reading
Learn more about the latest research and global efforts in Diseases — General.
Live Poll
Should private companies prioritize research for neglected diseases over profitable drug development projects?
